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secreting substances that caused hormone-related symp-
toms. Therefore, it was necessary to develop so-called “gen-
eral tumor markers.” The most important ones so far have 
been chromogranin A and neuron-specific enolase (NSE). 
Chromogranin A is the most important general biomarker 
for most NETs with a sensitivity and specificity somewhere 
between 60 and 90%. NSE has been a relevant biomarker for 
patients with high-grade tumors, particularly lung and gas-
trointestinal tract tumors. Serotonin and the breakdown 
product urinary 5-hydroxyindoleacetic acid (U-5-HIAA) is still 
an important marker for diagnosing and follow-up of SI 
NETs. Recently, 5-HIAA in plasma has been analyzed by high-
performance liquid chromatography and fluorometric de-
tection and has shown good agreement with U-5-HIAA anal-
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 Abstract 
 Biomarkers have been the mainstay in the diagnosis and fol-
low-up of patients with neuroendocrine tumors (NETs) over 
the last few decades. In the beginning, secretory products 
from a variety of subtypes of NETs were regarded as bio-
markers to follow during diagnosis and treatment: serotonin 
for small intestinal (SI) NETs, and gastrin and insulin for pan-
creatic NETs. However, it became evident that a large num-
ber of NETs were so-called nonfunctioning tumors without 
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ysis. In the future, we will see new tests including circulating 
tumor cells, circulating DNA and mRNA. Recently, a NET test 
has been developed analyzing gene transcripts in circulating 
blood. Preliminary data indicate high sensitivity and specific-
ity for NETs. However, its precise role has to be validated in 
prospective randomized controlled trials which are ongoing 
right now.   © 2017 S. Karger AG, Basel 
 Introduction 
 Over the years, a number of general and specific circu-
latory biomarkers ( Table 1 ) have been developed for the 
diagnosis and follow-up of patients with neuroendocrine 
tumors (NETs). The most important ones will be dis-
cussed in detail in the present paper. New biomarkers, 
such as circulating DNA, mRNA and circulating tumor 
cells, are currently under development; however, they are 
not ready for clinical routine use and have to be evaluated 
in prospective randomized trials.
 Small Intestinal NETs 
 NETs originating from the small intestine (midgut) 
may result in functional symptoms due to the secretion of 
various peptides and hormones and most notably 5-hy-
droxytryptamine or serotonin. This is a tryptophan-de-
rived biogenic amine involved in smooth muscle contrac-
tion, blood pressure regulation, and both peripheral and 
central nervous system neurotransmission. Approxi-
mately 2% of dietary tryptophan is converted into sero-
tonin. Serotonin is synthesized and stored in enterochro-
maffin cells of the gastrointestinal tract (80% of total body 
serotonin content), in dense granules of platelets (storage 
only), and in the serotoninergic neurons of the central 
nervous system. The urinary breakdown metabolite of se-
rotonin is urinary 5-hydroxyindoleacetic acid (U-5-
HIAA), which is particularly useful in the diagnosis and 
follow-up of NETs with carcinoid syndrome  [1–4] . Se-
rum measurements of serotonin are possible in these pa-
tients; however, large individual variations make them 
unreliable for diagnosis and in follow-up  [3] . Universally, 
U-5-HIAA is the most frequently performed assay in the 
clinical setting of the carcinoid syndrome. Serum 5-HIAA 
may represent a future tool for diagnosing and follow-up 
of small intestinal (SI) NETs with carcinoid syndrome. A 
couple of recent trials have demonstrated a good agree-
ment between measurements of U-5-HIAA and serum 
5-HIAA  [5–7] . Indeed, plasma and urine 5-HIAA dis-
played similar diagnostic sensitivities and specificities, 
warranting, however, further validation on larger patient 
populations. The carcinoid syndrome also has other me-
diators than serotonin, such as substance P and neuroki-
nin A (tachykinins).
 Performance of 5-HIAA in Diagnosis 
 The overall sensitivity and specificity of U-5-HIAA in 
the presence of the carcinoid syndrome is of the order of 
70 and 90%, respectively  [1, 2] . Midgut NETs are most li-
able to produce the carcinoid syndrome with U-5-HIAA 
elevation, thus attesting to a high specificity (>90%) in 
this setting. Foregut and hindgut NETs produce less se-
rotonin than midgut tumors  [1, 3] . U-5-HIAA levels may 
also depend on tumor volume and may be normal in pa-
tients with nonmetastatic tumors. Levels may be normal 
even in the presence of the carcinoid syndrome, particu-
larly in subjects without diarrhea; however, this is a rare 
event  [3] . In functional SI NETs, discriminating perfor-
mances may vary depending on whether the cutoffs are 
high or low. Meijer et al.  [1] demonstrated that a low-
level U-5-HIAA cutoff value (2.8 mmol/mol creatinine) 
yielded 68% sensitivity and 89% specificity, whereas a 
higher cutoff (6.7 mmol/mol creatinine) improved speci-
ficity to 98% at the expense of a lower sensitivity (52%). 
Thus, in order to confidently exclude an SI NET, a low-
level cutoff value may be preferred; to confirm the pres-
ence of an SI NET, a high-level cutoff value is better. Some 
patients with the carcinoid syndrome excrete nonhy-
droxylated indole acids, not measured as U-5-HIAA. 
There appears to be an inconstant correlation between 
the U-5-HIAA level and the clinical severity of the carci-
noid syndrome; this may be related to a fluctuating re-
lease of serotonin from tumors, such that the correlation 
may not be reliable. The possibility of carcinoid syndrome 
associated with normal 5-HIAA levels could be explained 
by the presence of other circulating biologically active 
molecules, which may often be secreted or co-secreted in 
patients with lung and midgut NETs.
 Recent data have examined U-5-HIAA as a prognostic 
factor in these patients: while interesting data have 
emerged, the expert group felt that data have not con-
firmed U-5-HIAA levels to be a  consistently reliable  prog-
nostic  factor in this disease. To illustrate this, two studies 
including 256 and 139 patients with SI NETs showed that 
while elevated U-5-HIAA levels were predictive of poor 
outcome at univariate analysis, this did not remain sig-
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nificant at multivariate analysis  [4, 8] . In another study 
examining 76 patients, those with persistent moderately 
increased U-5-HIAA levels ( ≤ 20 mmol/mol creatinine) 
had a more favorable outcome compared to those with 
greatly elevated levels  [9] . A further study in a mixed tu-
mor group including 119 patients (53 with SI NETs) in-
terestingly found high U-5-HIAA to be an independent 
survival factor  [10] . 
 Assays for 5-HIAA 
 While several assays are available to measure U-5-
HIAA (thin-layer chromatography, enzyme immunoas-
say, gas chromatography, and gas chromatography-mass 
spectrometry)  [11–14] , the use of high-performance liq-
uid chromatography (HPLC) is most frequently em-
ployed. HPLC with electrochemical detection is currently 
recommended; however, automated assays  [15] or those 
using mass spectrometry  [14] may be available in some 
laboratories. Liquid chromatography tandem mass spec-
trometry assay appears to be a rapid assay with little ne-
cessity for repeat analyses because of chromatographic 
interference or dilutions  [14] . A further automated meth-
od with on-line solid-phase extraction and HPLC and flu-
orometric detection has recently been shown to have in-
creased precision and faster throughput compared to the 
manual solvent extraction method  [16] . Whatever tech-
nique is used, it should be performed in accredited labo-
ratories. Serum 5-HIAA is analyzed by liquid chromatog-
raphy tandem mass spectrometry assay  [5–7] .
 Conditions for an Optimal Assay  
 Urine should be collected and measured in plastic con-
tainers. Acid should be added to ensure sterility and 
hence stability. The sample should be stored in a refrig-
erator until analysis. All the urine passed over 24 h should 
be collected into the container, preferably by using a mea-
suring jug. Collecting should be started at a defined time 
point following urination, and after that urine should be 
collected until the same time point the next day (a precise 
24-h collection). Written instructions should be handed 
out including food and medication precautions ( Table 2 ). 
 Care in Interpreting U-5-HIAA Levels 
 Intraindividual variation of U-5-HIAA is also possi-
ble and this variation may be high; therefore, 2 consecu-
tive 24-h collections should be performed and the mean 
 Table 1. General and specific biomarkers currently used for the management of patients with neuroendocrine 
tumors
General tumor markers Related indications
Chromogranin A Almost all NETs (follow-up, limited in diagnosis)
Neuron-specific enolase Atypical carcinoids, lung NEC, microcytoma
Pancreatic polypetide Pancreatic NET
α-Subunit, β-hCG Pancreatic, lung NET
Specific tumor markers Related indications
Serotonin, 5-HIAA Well differentiated NET
Gastrin Zollinger-Ellison syndrome 
Insulinoma Insulin-secreting pancreatic NET
Glucagon, VIP, somatostatin Well differentiated pancreatic NET
Catecholamines Pheocromocytoma/paraganglioma
Calcitonin Medullary thyroid cancer and pancreatic NET
PTHrp, ACTH, CRH, GHRH Syndromes from (ectopic) mainly lung or pancreatic NET
NTpro-BPN (marker of ventricular dysfunction) Carcinoid syndrome (carcinoid heart disease)
 NET, neuroendocrine tumor; NEC, neuroendocrine carcinoma; 5-HIAA, 5-hydroxyindolacetic acid; VIP, 
vasoactive intestinal peptide; PTHrp, parathormone-related peptide; ACTH, adrenocorticotropin hormone; 
CRH, corticotropin-releasing hormone; GHRH, growth hormone-releasing hormone; NTpro-BPN, N-terminal 
pro-brain natriuretic peptide.
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value of these 2 can be taken, especially when the collec-
tion is required for diagnosis. A single specimen may be 
sufficient for follow-up purposes. Certain comorbidities 
or associated disorders may have effects on the concen-
tration of U-5-HIAA. Falsely low U-5-HIAA levels may 
be encountered in patients with renal impairment and 
those on hemodialysis. In addition, U-5-HIAA may be 
increased in untreated patients with malabsorption, who 
have increased urinary tryptophan metabolites. Such pa-
tients include those with gluten-sensitive enteropathy 
(celiac disease), tropical sprue, Whipple disease, intesti-
nal stasis, and cystic fibrosis (chronic intestinal obstruc-
tion)  [1, 17] ; plasma 5-hydroxytryptamine, but not U-
5-HIAA, has been elevated in diarrhea-predominant ir-
ritable bowel syndrome  [18] . A small number of normal 
individuals may have elevated U-5-HIAA and, therefore, 
other objective findings should be used in conjunction 
with tumor marker analysis to support the diagnosis of 
an SI NET  [19] . The following food substances are rich 
in dietary tryptophan and, therefore, patients should ab-
stain from these for 3 days prior to urinary collection: 
plums, pineapples, bananas, eggplants (aubergines), to-
matoes, avocados, and walnuts  [2, 20, 21] . Even certain 
medications may increase or decrease U-5-HIAA levels 
( Table 2 ).
 Patients are frequently treated with somatostatin ana-
logues and these are known to decrease levels of U-5-
HIAA; where possible, assays for diagnostic purposes 
should be made in patients not on somatostatin ana-
logues, while in the follow-up setting, comparisons should 
be performed in patients on stable or comparable doses. 
Recently, significantly elevated levels of U-5-HIAA have 
been confirmed as a negative predictor for overall sur-
vival, except when considered with other biomarkers and 
grading, suggesting its use to assess carcinoid syndrome 
without having a prognostic value  [22] . 
 Pancreatic NETs 
 Insulinoma: 72-h Fast 
 NETs secreting insulin are termed insulinomas and 
are almost exclusively intrapancreatic in nature. Exces-
sive insulin secretion leading to hypoglycemia usually re-
sults in a combination of neurologic (diplopia, blurred 
vision, confusion, abnormal behavior and amnesia, sei-
zures, coma, etc.) and autonomic (sweating, weakness, 
hunger, tremor, nausea, feelings of warmth, anxiety, pal-
pitations) symptoms. Such symptoms are usually related 
to the degree of insulin-induced hypoglycemia, but may 
be nonspecific. Hypoglycemia-induced clinical signs are 
classically present in the early morning preprandial 
phase or may be exercise-induced. The diagnosis is sug-
gested in the presence of: (1) symptoms of hypoglycemia; 
(2) glucose <2.2 mmol/L (40 mg/dL; others use a thresh-
old of <3 mmol/L, 55 mg/dL); and (3) relief of symptoms 
with administration of glucose  [23] . This is known as the 
Whipple triad. The 72-h fast is the gold standard for di-
agnosing insulinoma and relates to the integrity of the 
patient’s endogenous suppression of insulin in the face 
of hypoglycemia. The fast attests to autonomous insulin 
secretion and the failure of appropriate insulin suppres-
sion in the presence of hypoglycemia. Factitious hypo-
glycemia secondary to the exogenous use of insulin is 
suspected on the finding of high (often very high) serum 
insulin in combination with suppression of C-peptide. 
Sulfonylureas and related insulin secretagogues result in 
a clinical picture similar to patients with insulinoma and 
may be diagnosed by a positive drug screen  [24] . An 
overall approach to diagnosing and managing insulino-
ma has been provided elsewhere in another consensus 
statement  [25] . 
 Table 2. Factors interfering with measurements of urinary 
5-hydroxyindole acetic acid
Foods Drugs
Factors producing false-positive results
Avocado Acetaminophen
Banana Acetanilide
Chocolate Caffeine
Coffee Fluorouracil
Eggplant (aubergine) Guaifenesin
Pecan L-DOPA
Pineapple Melphalan
Plum Mephenesin
Tea Metamphetamine
Walnuts Methocarbamol
Methysergide maleate
Phenmetrazine
Reserpine
Salycylates
Factors producing false-negative results
None Corticotropin
p-chlorophenylalanine
Chlorpromazine
Heparin
Imipramine
Isoniazid
Methenamine maleate
Methyldopa
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 Supervised 72-h Fast 
 This test has been verified as the gold standard in estab-
lishing a biochemical diagnosis of insulinoma  [26] . Pa-
tients should be hospitalized in a specialist unit experi-
enced in performing the test. A 72-h period is universally 
recognized as the most appropriate duration  [25] , although 
some groups have proposed a shorter fast of 48 h  [27, 28] . 
Symptoms appear within 12 h for one-third of patients, 
within 24 h for 80%, within 48 h for 90%, and within 72 h 
for nearly 100%  [29] . Absolute values of glucose and insu-
lin are the most important variables and any measurable 
insulin is abnormal when blood glucose drops to 2.5 mol/L 
(45 mg/dL). Assays used for the determination of insulin, 
proinsulin, C-peptide and β-hydroxybutyrate may vary 
but should be performed in accredited laboratories. Very 
occasionally, an insulinoma is only revealed by hypoglyce-
mia induced by a mixed meal rather than fasting. 
 Patient Information Scheme 
 A detailed description of the fast should be provided 
to all patients with an information card to help in symp-
tom identification. Patients should stay off all foods, ex-
cept for plain water, black tea or coffee, and essential 
medications (particularly hypoglycemic agents; e.g., sul-
fonylureas).
 Procedure 
 The timing of the 72-h fast is not critical – some teams 
prefer to perform the test early in the week when staffing 
levels may be higher, thus avoiding prolonging the test 
into the weekend. An oral glucose tolerance or mixed 
meal test can be performed before the fast. The patient 
should be monitored in a supervised environment and 
fasting should be accompanied by an intravenous line.
 – Absolute blood (venous) determinations should be 
performed at least 2–4 times per day and when the pa-
tient describes symptoms. The test interpretation 
should be made using laboratory blood glucose assays; 
bedside measurements can be used in the presence of 
clinical symptoms to determine if more definitive 
measurements should be made.  
 – Blood should also be drawn for insulin measurement 
concurrently with glucose estimations, and assay for 
insulin and C-peptide when hypoglycemia is con-
firmed.  
 – β-Hydroxybutyrate (or urinary ketones) should be 
measured at the end of the test in order to confirm the 
validity of the fast. A low level of hydroxybutyrate in 
the presence of hypoglycemia confirms inappropriate 
insulin or insulin-like hormone secretion.  
 – A urinary assay for sulfonylureas should be performed 
as a specific request: 
 • Not all drugs are detected, e.g., repaglinide  [24] ; 
false-positive results may also occur; e.g., on 
paracetamol.  
 • The results need to be confirmed with the local lab-
oratory. 
 Definition of Hypoglycemia 
 The endpoint of the test is documented hypoglycemia: 
 – Documented blood glucose levels 2.2 mmol/L (/40 
mg/dL; according to some <3 nmol/L, 55 mg/dL; levels 
may depend on age and sex). 
 – Concomitant insulin levels >6 μU/L ( ≥ 36 pmol/L;  ≥ 3 
μU/L by ICMA). 
 – A β-hydroxybutyrate level –2.7 mmol/L can be used as 
a surrogate marker to confirm the validity of the fast 
and inappropriate insulin suppression.  
 – A glucagon test immediately after 72-h fasting in pa-
tients without definite results has also been recom-
mended. 
 – Exercise test immediately after 72-h fasting in patients 
without definitive results may be performed in a su-
pervised setting. 
 – Use of a ratio of insulin to glucose to aid in the diag-
nosis is not recommended. 
 Gastrinoma (Zollinger-Ellison Syndrome) 
 Standards for the Diagnosis of a Gastrinoma: Secretin 
Test 
 The diagnosis of the Zollinger-Ellison syndrome (ZES) 
can be established by the demonstration of elevated fast-
ing serum gastrin (FSG) in the presence of low gastric pH. 
FSG alone is not adequate to make the diagnosis of ZES 
because hypergastrinemia can be seen in patients with 
hypo- or achlorhydria associated with chronic atrophic 
fundus gastritis (e.g., pernicious anemia) and in other 
conditions with hyperchlorhydria (e.g.,  Helicobacter py-
lori  infection, gastric outlet obstruction, renal failure, an-
tral G-cell syndromes, short bowel syndrome, and re-
tained antrum). In addition, the use of chronic proton 
pump inhibitors (PPIs) leads to high FSG levels and, 
therefore, gastrin provocative tests are needed to establish 
the diagnosis of ZES. Indeed, in a recent prospective anal-
ysis, up to two-thirds of gastrinoma patients were found 
to have FSG values being <10-fold normal  [30] . The gold 
standard is the secretin test  [30–34] . This hormone, when 
given intravenously, provokes an increase in serum gas-
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trin and, secondarily, in gastric acid secretion. The most 
reliable data concerning the secretin test have emanated 
from the National Institutes of Health (NIH) studies in 
patients with sporadic and multiple endocrine neoplasia 
type 1-associated gastrinomas  [30–34] . Consensus guide-
lines have described the criteria used for establishing the 
diagnosis of gastrinoma  [33] ; however, according to the 
expert committee, acid output studies are available to 
only a limited number of groups (including those expert 
groups). For the NIH group, the secretin test was useful 
in diagnosing ZES regardless of the extent or locations of 
the tumor, the presence or absence of multiple endocrine 
neoplasia type 1 or the level of FSG (less than or greater 
than 1,000 pg/mL)  [31] . In patients with fasting gastrin 
<1,000 pg/mL, the sensitivity of the secretin test using the 
criterion delta (increase from a prestimulation level) gas-
trin of  ≥ 110 pg/mL was 93% (95% CI, 76–99) and for a 
delta gastrin of 200 pg/mL, sensitivity was 85% (95% CI, 
66–96) ( p > 0.05)  [31] . The same group recently reported 
their prospective experience with gastrin provocative 
tests in 293 ZES patients from the NIH and compared 
them with 537 ZES patients from the literature and 462 
non-ZES patients (again from the literature)  [33] . This 
group established a delta gastrin of  ≥ 120 pg/mL in pa-
tients with a <10-fold increase as having the highest sen-
sitivity and specificity (94 and 100%, respectively)  [33] . 
They also demonstrated the clear superiority of the secre-
tin provocation test compared to the calcium test (94 vs. 
62%). However, in ZES patients with a negative secretin 
test, the calcium provocation test may be helpful  [33] . The 
expert group noted that certain groups had difficulty in 
obtaining secretin, hindering accurate diagnosis. 
 Indications for Gastrin Provocative Tests: Secretin 
Test 
 – The secretin test is performed to confirm a biochemi-
cal diagnosis of gastrinoma. The test may be repeated 
during the follow-up after curative surgery. FSG 
should be performed prior to the secretin test; if FSG 
>1,000 pg/mL, a secretin test is not necessary. When 
FSG lies between 200 and 1,000 pg/mL, a secretin test 
should be performed. 
 – The following conditions should also be documented: 
 • Absence of fundic atrophic gastritis: 
 – Antral and fundic biopsies (± serology for anti-
parietal and intrinsic factor antibodies) 
 – 24-h pH-metry (loss of diurnal pH course); basal 
acid output is recommended before and after se-
cretin where possible; BAO >15 mmol/h is highly 
suggestive of diagnosis of ZES; a random pH anal-
ysis during upper gastrointestinal endoscopy was 
also suggested (this requires further evaluation) 
 –  Helicobacter pylori  testing  
 • Other conditions leading to high FSG should be 
considered including gastric outlet obstruction, re-
nal failure, antral G-cell syndromes, short bowel 
syndrome, and retained gastric antrum. 
 • Treatment with PPIs interferes with basal FSG, as 
well as the secretin test  [35] . 
 Preparation for Secretin Test 
 – If possible, PPIs should be interrupted 10 days to 2 
weeks prior to the test (PPIs for 2 weeks can be re-
placed by H 2 blockers); interruption of H 2 blockers for 
approximately 48 h prior to the test; however, inter-
ruption of all antisecretory medications should be in-
dividually adapted and patients should be warned of 
reapparition of symptoms and should have sufficient 
antisecretory medications to start should they become 
symptomatic; certain patients may have to be hospital-
ized during antisecretory therapy withdrawal.  
 – Heparinized vacutainers are used and should be la-
beled and placed in ice.  
 Secretin Test  
 – Patient fasting overnight, for 12–14 h 
 – Site indwelling intravenous cannula 
 – Kabi-secretin (2 U/kg body weight) is given by intra-
venous bolus 
 – Serum gastrin:  
 • Baseline measured at –15 and –1 min before the test 
 • 2, 5, 10, 15, 20, and 30 min after secretin 
 – Samples stored on ice ( immediate transfer to labora-
tory) 
 Possible side effects of the secretin test include flush 
and an allergic reaction.
 Interpretation of Results 
 – Delta gastrin of at least 200 pg/mL any time during the 
test is considered as positive.  
 – The NIH has recently published a delta gastrin of  ≥ 120 
pg/mL as having a high sensitivity and specificity (94 
and 100%, respectively)  [33] . 
 General Biomarkers for NETs 
 Serum Chromogranin A 
 Chromogranin A (CgA) is an acid glycoprotein with 
439 amino acids that is present in the secretory dense core 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.1
5.
11
 - 
10
/1
6/
20
17
 5
:0
7:
06
 P
M
 Biochemical Markers Neuroendocrinology 2017;105:201–211
DOI: 10.1159/000472254
207
granules of most neuroendocrine cells  [36] . The chromo-
granin family consists of at least 3 different water-soluble 
acidic glycoproteins (CgA, CgB, and secretogranin II, 
sometimes called chromogranin C). Upon stimulation, 
CgA and other peptide hormones and neuropeptides are 
released. CgA is also secreted from neuroendocrine-de-
rived tumors including foregut, midgut and hindgut gas-
trointestinal NETs, pheochromocytomas, neuroblasto-
mas, medullary thyroid carcinomas, some pituitary tu-
mors, functioning and nonfunctioning pancreatic NETs, 
and other amine precursor uptake and decarboxylation 
tumors. CgA has also been widely used as an immunohis-
tochemical marker in NETs  [37] and is recognized as the 
most effective. CgA has been recognized as a general se-
rum marker, as it is co-secreted in tumors with the amines 
and peptides that are present in the neurosecretory gran-
ules  [38] and can be elevated in both functionally active 
and nonfunctional NETs. Specificity of elevated CgA is 
related to tumor type and is almost universally elevated 
in patients with gastrinoma  [39–41] ; it is often high in 
NETs of midgut origin and in nonfunctioning pancreatic 
NETs. Differences in tumor cell type, histological differ-
entiation and tumor volume may influence the level of 
CgA and interpretation may also depend on the assay 
used in measurement.
 Reliability of CgA in Patients with NETs 
 Overall, CgA has been found to be clinically informa-
tive and moderately sensitive in the majority of studies 
devoted to this topic. CgA was found to be more sensitive 
than neuron-specific enolase (NSE) in all subgroups of a 
large mixed NET patient cohort ( n = 128)  [42] . While 
performances have been limited in low-level cutoffs due 
to the overlap with control populations, very high levels 
of serum CgA are rarely found outside the setting of NETs 
with the exception of patients on gastric acid secretory 
blockers, especially PPIs  [43] or those with hypergastrin-
emia. Specificity of CgA in the diagnosis of NETs depends 
on the tumor type and burden (100% specificities have 
been reported in patients with metastatic disease  [44–
47] ), the quality of the control populations used and the 
cutoff values employed  [40, 48] . Elevated CgA was found 
to be more sensitive than high U-5-HIAA levels in pa-
tients with metastatic midgut lesions (87 vs. 76%, respec-
tively)  [4] . Nobels et al.  [39] demonstrated a significant 
positive relation between the serum levels of CgA and the 
tumor mass in NETs; however, the distinction between 
high and low tumor volume may be open to question. 
This study also confirmed tissue specificities as high CgA 
concentrations were found in all patients with gastrino-
ma, although small in size and tumor volume  [39] . In a 
mixed series of 128 patients with NETs, increased CgA 
levels were found in 29 and 67% of patients with locore-
gional or metastatic disease, respectively  [42] . A prognos-
tic value of CgA in patients with NET has not been re-
ported in several studies  [4, 49, 50] .
 False-Positive Elevation of CgA May Occur in the 
Following Circumstances 
 – Impaired renal function  [51, 52] 
 – Parkinson disease, untreated hypertension and preg-
nancy 
 – Steroid treatment or glucocorticoid excess, which can 
lead to upregulation of CgA mRNA  [53, 54] 
 – Chronic atrophic gastritis (type A)  [55] 
 – Treatment with antisecretory medications, especially 
PPIs  [43] 
 Chronic elevation of gastrin levels provokes hyperpla-
sia of the neuroendocrine cells of the stomach and these 
cells are able to secrete CgA  [56] . In patients with chron-
ically elevated CgA and ZES, it was demonstrated that the 
CgA concentrations can be normalized by gastrectomy 
alone, without resection of the gastrin-producing tumor 
 [57] . A more recently described case report of false-posi-
tive CgA was due to the presence of heterophile antibod-
ies (HAb), which can bind to animal antigens and may be 
present in up to 40% of the normal population  [58] ; in the 
CgA immunometric assays, HAb interferences may be 
circumnavigated by using an HAb-blocking tube  [59] .
 Assays for CgA 
 A recognized international standard for CgA assay is 
not available and variations in assay types may influence 
results. Several assays for measurements of intact CgA 
and cleavage products have been developed  [38, 60] . The 
complexity of assays is explained by the presence of sev-
eral CgA-related peptides from human and other species 
 [61] and CgA processing varies according to neuroendo-
crine cells/tissues  [62, 63] . A competitive radioimmuno-
assay can detect circulating CgA, with the use of purified 
full-length human CgA  [45, 64] . Commercial CgA kits 
differ in the types of antibodies used (monoclonal vs. 
polyclonal) and include enzyme detection (ELISA) and 
radioimmunoassay. Differences in methods of standard-
ization have also led to heterogeneity. Generally, mea-
surement of intact CgA in plasma has greater sensitivity 
for the diagnosis of NETs than the measurement of frag-
ments  [38, 65] . Stridsberg et al.  [48] compared the 3 com-
mercially available kits in a group of NET patients and 
found sensitivities to vary between 67 and 93%, while 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.1
5.
11
 - 
10
/1
6/
20
17
 5
:0
7:
06
 P
M
 Oberg   et al.
 
Neuroendocrinology 2017;105:201–211
DOI: 10.1159/000472254
208
specificities were >85% for all 3. A recent multicenter pro-
spective comparison between 2 methods, immunoradio-
metric and ELISA, found a 36% clinical discordance rate 
 [66] . These results were mirrored with a difference of 
5-fold interlaboratory variation rate in a recent Italian 
study aimed at assessing CgA detection performance as 
applied to immunoradiometric and ELISA assays  [67] . A 
further prospective analysis underlined that CgA is a 
practical marker in patients with NETs, however, with 
limited diagnostic power; using ROC curves, a cutoff of 
53 ng/mL for IRMA and 16 U/L for ELISA for discrimi-
nating between healthy controls and NET patients yield-
ed only moderate sensitivities (71.3 and 83%, respective-
ly) and specificities (71 and 85%, respectively)  [47] . 
 General Remarks on CgA 
 – CgA is the most practical and useful general serum tu-
mor marker in patients with NETs. 
 – Elevated CgA can occur in normal individuals and in 
patients with non-NETs although the levels are usu-
ally lower than in patients with NETs.  
 – Sensitivity of elevated CgA varies according to NET 
tumor type and volume. 
 CgA Assays and Interpretation  
 – Reference laboratories should be preferred for clinical 
samples assays. 
 – Reference intervals and individual patient results dif-
fer significantly between different CgA assays and can-
not be directly compared. 
 – Serial measurements should be performed using the 
same assay. 
 – If assays are changed, patients should undergo a new 
baseline measurement. 
 – False-positive results are possible in patients with hy-
pergastrinemia (especially on antisecretory medica-
tions or chronic atrophic gastritis type A) and in the 
presence of HAbs (care in patients with autoimmune 
diseases or those sensitized to rodent proteins (mouse 
monoclonal antibodies). 
 – Where possible, PPIs should be interrupted, leaving a 
clearance of at least 3 half-lives, prior to CgA plasma 
sampling. 
 Other and Emerging Biomarkers in Clinical Use 
 Serum NSE is considered a tumor marker in NETs  [39, 
68] and is elevated in 30–50% of the patients, particularly 
in those with high-grade tumors (poorly differentiated 
tumors). The prognostic role of NSE as a biomarker has 
been evaluated as well  [69, 70] . Pro-gastrin-releasing pep-
tide has demonstrated clinical benefit in atypical lung car-
cinoids and other high-grade lung NETs  [68, 71] .
 Pancreastatin (a part of the CgA molecule) is a good 
marker for gastrointestinal NETs. It has been claimed to 
be better than CgA; however, there are only few assays 
available, mainly for preclinical routine use  [72] . 
 Neurokinin A has been suggested to be a good/reliable 
marker in SI NET  [73, 74] .
 In functional tumors, measurements of specific hor-
mones or other biomarkers can be useful. ACTH and cor-
tisol are assessed for the diagnosis and monitoring of 
NET-associated ectopic Cushing syndrome, whereas 
PTHrp for hypercalcemia associated with PTHrp-secret-
ing NETs  [75] .
 NT-proBNP is a valid marker in the clinical evaluation 
of carcinoid heart disease  [76] .
 Blood measurements of neuroendocrine gene tran-
scripts have demonstrated significant diagnostic and 
prognostic potential in recent studies (NET-test). The 
precise role of these analyses has to be expected in future 
prospective trials  [77–79] .
 Finally, circulating tumor cells is another new tool for 
diagnosing and follow-up of NET patients  [80] . However, 
it also needs to be evaluated in prospective trials.
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